Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Bertoli

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
Blood Advances|October 17, 2024
Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemiaRomane Joudinaud, Augustin Boudry, Laurène Fenwarth, et al.
Leukemia Research|July 25, 2022
Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in FrancePierre-Yves Dumas, Sarah Bertoli, Caroline Bonmati, et al.
Blood Advances|February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohortEdmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
Blood Cancer Journal|August 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemiaFrançois Vergez, Laetitia Largeaud, Sarah Bertoli, et al.
American Journal of Hematology|November 18, 2024
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registriesChristian Récher, Pierre-Yves Dumas, Emilie Bérard, et al.
Leukemia|November 14, 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registriesChristian Récher, Christoph Röllig, Emilie Bérard, et al.
Blood Cancer Journal|July 12, 2022
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registriesEmilie Bérard, Christoph Röllig, Sarah Bertoli, et al.
Nature Communications|May 26, 2021
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patientsFlorent Malard, Anne Vekhoff, Simona Lapusan, et al.
Blood Cancer Journal|August 21, 2025
Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO studyJules Higué, Corentin Orvain, Pierre-Yves Dumas, et al.
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Blood Advances|October 17, 2024
Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemiaRomane Joudinaud, Augustin Boudry, Laurène Fenwarth, et al.
Leukemia Research|July 25, 2022
Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in FrancePierre-Yves Dumas, Sarah Bertoli, Caroline Bonmati, et al.
Blood Advances|February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohortEdmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
Blood Cancer Journal|August 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemiaFrançois Vergez, Laetitia Largeaud, Sarah Bertoli, et al.
American Journal of Hematology|November 18, 2024
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registriesChristian Récher, Pierre-Yves Dumas, Emilie Bérard, et al.
Leukemia|November 14, 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registriesChristian Récher, Christoph Röllig, Emilie Bérard, et al.
Blood Cancer Journal|July 12, 2022
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registriesEmilie Bérard, Christoph Röllig, Sarah Bertoli, et al.
Nature Communications|May 26, 2021
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patientsFlorent Malard, Anne Vekhoff, Simona Lapusan, et al.
Blood Cancer Journal|August 21, 2025
Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO studyJules Higué, Corentin Orvain, Pierre-Yves Dumas, et al.
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
Pageof 10